Squamous Cell Carcinoma of the Head and Neck

Oncology
13
Pipeline Programs
13
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
3
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 10 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
MEDI4736Phase 31 trial
OlaparibPhase 21 trial
Active Trials
NCT02882308Completed41Est. Jan 2020
NCT02551159Completed823Est. May 2021
CT
1 program
1
TQB2450+cisplatin or carboplatin + 5-FluorouracilPhase 31 trial
Active Trials
NCT03855384UnknownEst. May 2021
M&
Merck & Co.RAHWAY, NJ
3 programs
1
1
DalanterceptPhase 21 trial
EMD 1201081 + 5-FU + Cisplatin + CetuximabPhase 1Monoclonal Antibody1 trial
CetuximabN/AMonoclonal Antibody1 trial
Active Trials
NCT04672772Completed531Est. Jan 2022
NCT01360827Terminated13
NCT01458392CompletedEst. Sep 2015
Novartis
NovartisBASEL, Switzerland
1 program
1
Everolimus 10mg dailyPhase 21 trial
Active Trials
NCT01051791Terminated13Est. Aug 2016
Sanofi
SanofiPARIS, France
1 program
1
Cabazitaxel 10mg/m2Phase 11 trial
Active Trials
NCT01379339Completed40Est. Jan 2015
Providence Therapeutics
1 program
1
Intratumoral IpilimumabPhase 1Monoclonal Antibody
Celldex Therapeutics
1 program
1
KTN3379Phase 11 trial
Active Trials
NCT02473731Completed12Est. Oct 2016
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
PanitumumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00513383Completed34Est. Oct 2012
DS
Daiichi SankyoChina - Shanghai
1 program
1
PatritumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT02350712Completed15Est. Jun 2016
Shattuck Labs
Shattuck LabsAUSTIN, TX
1 program
1
SL-279252Phase 11 trial
Active Trials
NCT03894618CompletedEst. May 2023
Vaccinex
VaccinexROCHESTER, NY
1 program
1
VX15/2503Phase 11 trial
Active Trials
NCT03690986RecruitingEst. Nov 2027
Debiopharm
DebiopharmSwitzerland - Lausanne
1 program
CisplatinN/A1 trial
Active Trials
NCT02022098CompletedEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Chia Tai TianQing Pharmaceutical GroupTQB2450+cisplatin or carboplatin + 5-Fluorouracil
AstraZenecaMEDI4736
AstraZenecaOlaparib
Merck & Co.Dalantercept
NovartisEverolimus 10mg daily
Shattuck LabsSL-279252
VaccinexVX15/2503
Celldex TherapeuticsKTN3379
Daiichi SankyoPatritumab
SanofiCabazitaxel 10mg/m2
Merck & Co.EMD 1201081 + 5-FU + Cisplatin + Cetuximab
AmgenPanitumumab
Merck & Co.Cetuximab
DebiopharmCisplatin

Clinical Trials (14)

Total enrollment: 1,522 patients across 14 trials

NCT03855384Chia Tai TianQing Pharmaceutical GroupTQB2450+cisplatin or carboplatin + 5-Fluorouracil

Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）

Start: Jun 2019Est. completion: May 2021
Phase 3Unknown
NCT02551159AstraZenecaMEDI4736

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Start: Oct 2015Est. completion: May 2021823 patients
Phase 3Completed
NCT02882308AstraZenecaOlaparib

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Start: Oct 2016Est. completion: Jan 202041 patients
Phase 2Completed
NCT01458392Merck & Co.Dalantercept

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Start: Oct 2011Est. completion: Sep 2015
Phase 2Completed
NCT01051791NovartisEverolimus 10mg daily

Phase II Study of RAD001 Head and Neck Cancer

Start: Jan 2010Est. completion: Aug 201613 patients
Phase 2Terminated
NCT03894618Shattuck LabsSL-279252

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Start: Mar 2019Est. completion: May 2023
Phase 1Completed
NCT03690986VaccinexVX15/2503

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Start: Nov 2018Est. completion: Nov 2027
Phase 1Recruiting
NCT02473731Celldex TherapeuticsKTN3379

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Start: Oct 2015Est. completion: Oct 201612 patients
Phase 1Completed
NCT02350712Daiichi SankyoPatritumab

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Start: Dec 2014Est. completion: Jun 201615 patients
Phase 1Completed
NCT01379339SanofiCabazitaxel 10mg/m2

Cabazitaxel - PF Induction Chemotherapy

Start: Apr 2011Est. completion: Jan 201540 patients
Phase 1Completed
NCT01360827Merck & Co.EMD 1201081 + 5-FU + Cisplatin + Cetuximab

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Start: Aug 201013 patients
Phase 1Terminated
NCT00513383AmgenPanitumumab

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Start: Apr 2006Est. completion: Oct 201234 patients
Phase 1Completed
NCT04672772Merck & Co.Cetuximab

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Start: Dec 2020Est. completion: Jan 2022531 patients
N/ACompleted
NCT02022098DebiopharmCisplatin

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Start: Oct 2013Est. completion: Apr 2022
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
7m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
7m ago

Office Administrator

SystImmune
7m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
18m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
21m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
21m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,522 patients
13 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)